YWHAZ and hepatocellular carcinoma: Moreover, immunostaining results further confirmed that PXN and YWHAZ were both declined in siITGB1-treated HCC cells (Figure 6E, F, H, I; Supplementary Figure S5B–E; Supplementary Figure S6A–D).